Amarin Corporation plc: Business Overview, Financials & Competitive Analysis
Amarin Corporation plc is a pharmaceutical company that engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. ...
Cyborg Score thesis
Specialty cardiovascular pharmaceutical company with established commercial infrastructure and international expansion...
Read the full analyst-debate transcript →Get the Latest Amarin Corporation plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAmarin Corporation plc Overview
Pro stress-test →Amarin Corporation plc is a pharmaceutical company that engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Strategic Profile
Pro stress-test →The company sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. Amarin has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA.
Competitive Landscape
Pro stress-test →Amarin competes in the specialty cardiovascular pharmaceutical space against established players offering alternative triglyceride-lowering agents and lipid management therapies. Key competitors include major pharmaceutical companies with broader cardiovascular portfolios and other omega-3 or prescription lipid-focused manufacturers.
Industry Context
Amarin Corporation plc operates in Cardiovascular Drugs.
Key facts
Founded: 1989 · Headquarters: Dublin, Ireland · Employees: 501–1000 · Revenue: N/A · Market cap: N/A